Trevor Crosse
Partner, UK
Trevor is a Partner in Osborne Clarke's Intellectual Property team. He specialises in advising clients in the life sciences and healthcare sectors and has particular experience acting for biotech and pharmaceutical companies in complex patent disputes.
In recent years Trevor has advised pharma and biotech clients in patent disputes relating to many of the world's most successful biopharmaceutical products. Drawing on his scientific training in microbiology and immunology, he is regularly instructed to act in technically complex disputes before the English courts, and to manage related litigation around the globe.
In addition to his work on contentious matters, Trevor also advises clients in relation to supplementary protection certificates and regulatory exclusivity periods for medicinal products, helping them to develop sensible strategies to maximise protection for their innovative therapies. He also regularly advises in relation to commercial matters with an IP focus, including licensing deals, portfolio sales, and in connection with corporate fundraising transactions.
Trevor has been ranked as a "Rising Star" and "Notable Practitioner" by Managing IP's IP Stars and is recognised by Legal 500 for his work in the biotechnology and pharmaceuticals fields.
"Trevor Crosse is a biotechnology and pharmaceuticals patent litigation specialist, representing a number of major biopharmaceuticals clients in complex patent disputes."
Genentech
Acted for Genentech in a patent dispute relating to anti-IL17A/F antibodies for the treatment of psoriasis and rheumatoid arthritis, described by the judge as "one of the most complex patent cases [he had] ever tried".
AbbVie
Acted for AbbVie in a series of patent disputes relating to the world's then best-selling drug, Humira®.
Pfizer
Acted for Pfizer in proceedings relating to a prospective new class of treatments for osteoarthritis.
Insights
Unified Patent Court
UPC's former London Central Division competences to be reallocated between Paris, Munich and Milan
The provisional Paris-Munich competence split will continue until the new agreement comes into force in June 2024
03/07/2023
Read time
1m
Unified Patent Court
New judicial code of conduct addresses partiality concerns over UPC part-time technical judges
A new code supplements rules on judicial independence and impartiality in the Unified Patent Court Agreement and Statute
08/06/2023
Read time
2m
Unified Patent Court
French, German and Italian UPC local divisions to now offer English as alternative language of proceedings
A late-stage U-turn may not provide claimants with as much control over language of proceedings as it initially appears
01/06/2023
Read time
1m
Unified Patent Court
UPC publishes list of the acceptable languages before the local and regional divisions
The language of proceedings has caused controversy but the system adopted provides some flexibility for claimants
31/05/2023
Read time
2m
Intellectual property
UPC: former London Central Division competences provisionally split between Paris and Munich
With the UK no longer participating, cases due to have been heard in London will be heard for now in...
23/05/2023
Read time
1m
Intellectual property
Case management system problems for UPC underscore need to file opt-outs immediately
Application surge has highlighted that immediate action is required to avoid missing the 'sunrise' deadline
23/05/2023
Read time
2m
Intellectual property
Unified Patent Court offers new opportunities for effective enforcement of European patents
The UPC becomes operational on 1 June and introduces major changes to patent litigation across Europe
04/05/2023
Read time
6m
Intellectual property
Unified Patent Court: the basics
The UPC will soon be operational and getting to grips with the basics of how it operates is essential
15/02/2023
Read time
1m
Intellectual property
Long-arm jurisdiction: how remedies can extend to non-UPC states
UPC jurisdiction may be broader than it first appeared but questions remain about its reach over third-state defendants
07/02/2023
Read time
6m
Intellectual property
UPC action points: opting out of the EU's Unified Patent Court
Attitudes towards UPC opt-outs will depend on the proprietor and their patents but options should be weighed up now
03/02/2023
Read time
6m
Intellectual property
Unified Patent Court: an introduction to the UPC's general jurisdiction
Knowing the UPC's competence and international jurisdiction rules is vital to understand what it can hear and reach
26/01/2023
Read time
8m
